Meta-analysis of transarterial chemoembolization combined with cryoablation vs transarterial chemoembolization alone for ≥ 5 cm hepatocellular carcinoma

Figure 1 Flowchart of study inclusion. TACE: Transarterial chemoembolization; CRA: Cryoablation.

Figure 2 Risk of bias summary and bias graph of included studies. A: Risk of bias summary of included studies; B: Risk of bias graph of included studies.

Figure 3 1-, 2-, and 3-year survival. A: 1-year survival; B: 2-year survival; C: 3-year survival. TACE: Transarterial chemoembolization; CRA: Cryoablation; CI: Confidence interval.

Figure 4 Objective response rate and disease control rate. A: Objective response rate; B: Disease control rate. TACE: Transarterial chemoembolization; CRA: Cryoablation; CI: Confidence interval.

Figure 5 Postoperative alpha-fetoprotein, CD4⁺, and CD8⁺ level. A: Postoperative alpha-fetoprotein level; B: Postoperative CD4⁺ level; C: Postoperative CD8⁺ level. TACE: Transarterial chemoembolization; CRA: Cryoablation; CI: Confidence interval.

Figure 6 Complication rate. TACE: Transarterial chemoembolization; CRA: Cryoablation; CI: Confidence interval.